ACell

General Information
Business:

 

We are a leading regenerative medicine company focused on the development, manufacture and sale of products primarily used in acute care settings as part of the treatment and management of moderate to severe wounds and reinforcement of soft tissue surgical defects. Our products utilize our proprietary porcine urinary bladder matrix platform technology, which is designed to enhance the body’s ability to restore natural tissue and minimize scarring in the management of traumatic, surgical and chronic wounds, burns, hernias and other conditions requiring the reinforcement of soft tissue. 

Industry: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
Employees: 400
Founded: 1999
Contact Information
Address 6640 Eli Whitney Drive Columbia, MD 21046, US
Phone Number (800) 826-2926
Web Address http://www.acell.com
View Prospectus: ACell
Financial Information
Market Cap $344.6mil
Revenues $100.3 mil (last 12 months)
Net Income $-1.3 mil (last 12 months)
IPO Profile
Symbol ACLL
Exchange NASDAQ
Shares (millions): 5.0
Price range $14.00 - $16.00
Est. $ Volume $75.0 mil
Manager / Joint Managers UBS Investment Bank/ Barclays/ RBC Capital Markets
CO-Managers SunTrust Robinson Humphrey
Expected To Trade: 7/20/2020
Status: Withdrawn
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change